Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor

FASEB Journal

Volumn 20, Issue 12, 2006, Pages 2027-2035

  Browne, Cecille D ^a   Hindmarsh, Elizabeth J ^a,b   Smith, Jeffrey W ^a  

^a BURNHAM INSTITUTE   (United States)

^b Biology and Environment   (Australia)

Author keywords

KDR; Neovascularization; VEGF

Indexed keywords

FATTY ACID SYNTHASE; TETRAHYDROLIPSTATIN; THIOL ESTER HYDROLASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; LACTONE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOVASCULARIZATION (PATHOLOGY); PLACENTA; PRIORITY JOURNAL; UMBILICAL VEIN; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; VASCULAR ENDOTHELIUM;

CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FATTY ACID SYNTHETASE COMPLEX; HUMANS; LACTONES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; UMBILICAL VEINS;

EID: 33750129055     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5404com     Document Type: Article

References (36)

1. Kridel, S. J., Axelrod, F., Rozenkrantz, N., and Smith, J. W. (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64, 2070-2075
2. D'Angelo, G., Struman, I., Martial, J., and Weiner, R. I. (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. U. S. A. 92, 6374-6378
3. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., and Bohlen, P. (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17, 155-161
4. Kim, K. J., Li, B., Houck, K., Winer, J., and Ferrara, N. (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53-64
5. Ferrara, N., Hillan, K. J., Gerber, H. P., and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400
6. USFDA (2004) FDA approves first angiogenesis inhibitor to treat colorectal cancer. FDA News, PO4-23, www.fda.gov/bbs/topics/newss/2004/new01027. html
7. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L. B., Murray, L. J., Carver, J., Chan, E., Moss, K. G., Haznedar, J. O., Sukbuntherng, J., Blake, R. A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G., and Cherrington, J. M. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337
8. Demetri, G. D. Oosterom A. T. v., Blackstein, M., Garrett, C., Shah, M., Heinrich, M., McArthur, G. Judson, I, Baum, C. M., and Casali, P. G. (2005) Phase 3, multicenter, randomized, double-blind, placebo- controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. In 2005 ASCO Annual Meeting, Orlando, FL
9. Motzer, R. J., Rini B. I., Michaelson, M.D., Redman, G.G., Hudes, G.R., Wilding, G., Bukowski, R.M., George, D.J., Kim, S. T., and Baum, C. M. (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). In 2005 ASCO Annual Meeting, Orlando, FL
10. Tsukamoto, Y., Wong, H., Mattick, J. S., and Wakil, S. J. (1983) The architecture of the animal fatty acid synthetase complex. IV. Mapping of active centers and model for the mechanism of action. J. Biol. Chem. 258, 15312-15322
11. Chirala, S. S., Jayakumar, A., Gu, Z. W., and Wakil, S. J. (2001) Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimer. Proc. Natl. Acad. Sci. U. S. A. 98, 3104-3108
12. Rangan, V. S., Joshi, A. K., and Smith, S. (2001) Mapping the functional topology of the animal fatty acid synthase by mutant complementation in vitro. Biochemistry 40, 10792-10799
13. Joshi, A. K., Witkowski, A., and Smith, S. (1997) Mapping of functional interactions between domains of the animal fatty acid synthase by mutant complementation in vitro. Biochemistry 36, 2316-2322
14. Mattick, J. S., Nickless, J., Mizugaki, M., Yang, C. Y., Uchiyama, S., and Wakil, S. J. (1983) The architecture of the animal fatty acid synthetase. II. Separation of the core and thioesterase functions and determination of the N-C orientation of the subunit. J. Biol. Chem. 258, 15300-15304
15. Alo, P. L., Visca, P., Marci, A., Mangoni, A., Botti, C., and Di Tondo, U. (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77, 474-482
16. Nakamura, I., Kimijima, I., Zhang, G. J., Onogi, H., Endo, Y., Suzuki, S., Tuchiya, A., Takenoshita, S., Kusakabe, T., and Suzuki, T. (1999) Fatty acid synthase expression in Japanese breast carcinoma patients. Int. J. Mol. Med. 4, 381-387
17. Wang, Y., Kuhajda, F. P., Li, J. N., Pizer, E. S., Han, W. F., Sokoll, L. J., and Chan, D. W. (2001) Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 167, 99-104
18. Swinnen, J. V., Roskams, T., Joniau, S., Van Poppel, H., Oyen, R., Baert, L., Heyns, W., and Verhoeven, G. (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer. 98, 19-22
19. Rossi, S., Graner, E., Febbo, P., Weinstein, L., Bhattacharya, N., Onody, T., Bubley, G., Balk, S., and Loda, M. (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res. 1, 707-715
20. Bandyopadhyay, S., Pai, S. K., Watabe, M., Gross, S. C., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., Saito, K., Markwell, S. J., Wang, Y., Huggenvik, J., Pauza, M. E., Iiizumi, M., and Watabe, K. (2005) FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24, 5389-5395
21. Pizer, E. S., Wood, F. D., Heine, H. S., Romantsev, F. E., Pasternack, G. R., and Kuhajda, F. P. (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56, 1189-1193
22. Gansler, T. S., Hardman, W., 3rd, Hunt, D. A., Schaffel, S., and Hennigar, R. A. (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28, 686-692
23. Kuhajda, F. P., Pizer, E. S., Li, J. N., Mani, N. S., Frehywot, G. L., and Townsend, C. A. (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. U. S. A. 97, 3450-3454
24. Kuhajda, F. P., Jenner, K., Wood, F. D., Hennigar, R. A., Jacobs, L. B., Dick, J. D., and Pasternack, G. R. (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. U. S. A. 91, 6379-6383
25. Furuya, Y., Akimoto, S., Yasuda, K., and Ito, H. (1997) Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res. 17, 4589-4593
26. Pizer, E. S., Jackisch, C., Wood, F. D., Pasternack, G. R., Davidson, N. E., and Kuhajda, F. P. (1996) Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 56, 2745-2747
27. Pizer, E. S., Chrest, F. J., DiGiuseppe, J. A., and Han, W. F. (1998) Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 58, 4611-4615
28. Li, J. N., Gorospe, M., Chrest, F. J., Kumaravel, T. S., Evans, M. K., Han, W. F., and Pizer, E. S. (2001) Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 61, 1493-1499
29. Heiligtag, S. J., Bredehorst, R., and David, K. A. (2002) Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ. 9, 1017-1025
30. Patricelli, M. P., Giang, D. K., Stamp, L. M., and Burbaum, J. J. (2001) Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1, 1067-1071
31. Brown, K. J., Maynes, S. F., Bezos, A., Maguire, D. J., Ford, M. D., and Parish, C. R. (1996) A novel in vitro assay for human angiogenesis. Lab. Invest. 75, 539-555
32. Sin, N., Meng, L., Wang, M. Q., Wen, J. J., Bornmann, W. G., and Crews, C. M. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. U. S. A. 94, 6099-6103
33. Liu, Y., Patricelli, M. P., and Cravatt, B. F. (1999) Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. U. S. A. 96, 14694-14699
34. Zeng, H., Zhao, D., Yang, S., Datta, K., and Mukhopadhyay, D. (2003) Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. J. Biol. Chem. 278, 20738-20745
35. Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., and Lupu, R. (2004) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 101, 10715-10720
36. Menendez, J. A., Vellon, L., and Lupu, R. (2005) Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med. Hypotheses. 64, 997-1001